Hydrocortison Tiofarma (Hydrocortisone)

Hydrocortison Tiofarma is prescribed for several endocrine and inflammatory conditions where glucocorticoid therapy is indicated.

• Replacement therapy for primary or secondary adrenal insufficiency.
• Management of acute adrenal crisis to restore cortisol levels.
• Adjunct treatment of inflammatory and autoimmune disorders such as rheumatoid arthritis.
• Short‑term control of severe allergic reactions or skin conditions when systemic therapy is required.
• Supportive therapy in certain endocrine disorders where cortisol deficiency is present.

• Hydrocortison Tiofarma delivers hydrocortisone, which acts as an agonist at intracellular glucocorticoid receptors. Upon binding, the receptor‑ligand complex translocates to the nucleus and modulates gene transcription, up‑regulating anti‑inflammatory proteins and down‑regulating pro‑inflammatory cytokines. This results in reduced synthesis of prostaglandins and leukotrienes, suppression of immune cell activation, and restoration of physiological glucocorticoid activity in patients with adrenal insufficiency. The overall effect helps to control inflammation and maintain metabolic homeostasis.

Like other systemic glucocorticoids, Hydrocortison Tiofarma may be associated with a range of adverse reactions that vary in frequency and severity.

Common

• Increased appetite and mild weight gain.
• Fluid retention causing peripheral edema.
• Elevated blood glucose levels, particularly in diabetics.
• Mood alterations such as irritability or mild anxiety.

Serious

• Severe hypertension or cardiovascular events.
• Marked immunosuppression with heightened infection risk.
• Osteoporosis or increased fracture risk with long‑term therapy.
• Adrenal suppression leading to withdrawal symptoms if stopped abruptly.

When prescribing Hydrocortison Tiofarma, clinicians should evaluate several precautionary factors to minimize risks and ensure appropriate use.

• Assess for existing infections; treat before initiating therapy.
• Monitor blood pressure and glucose levels regularly during treatment.
• Use the lowest effective dose for the shortest duration possible.
• Evaluate bone health, especially in patients at risk for osteoporosis.
• Consider potential effects on pregnancy and lactation; discuss risks with the patient.
• Review concomitant medications that may increase glucocorticoid exposure.
• Educate patients on signs of adrenal insufficiency when tapering.

Hydrocortison Tiofarma can interact with other medicines, altering its efficacy or increasing adverse effects.

Avoid

• Concurrent use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce hydrocortisone levels.
• Combining with other systemic glucocorticoids, which can amplify immunosuppression and metabolic effects.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) due to increased risk of gastrointestinal ulceration.
• Anticoagulants such as warfarin, as glucocorticoids may affect coagulation parameters.
• Antidiabetic agents, because hydrocortisone can raise blood glucose and require dose adjustments.
• Vaccines, particularly live attenuated vaccines, may have reduced efficacy or increased infection risk.